Innovative start-up Genetoo has incorporated as a C-corporation and, after over a year of hard work, has licensed a NASA patent that will revolutionize the technology used in prosthetic implants. The company’s scientists, MDs, and biomedical engineers continue to collaborate on how to use this license to create bacteriophobic surfaces for integration in prosthetic implants, creating a better experience for both physicians and patients.
CEO of Genetoo, Chris Whitman, expressed his enthusiasm about the strategic importance of acquiring this technology, saying that the corporation’s highly skilled collaborators are working to take space technology and utilize it on earth in a way that will benefit patients who have received prosthetic implants.
By reducing bacteria adhesion, the technology gained from this patent will allow the creation of prosthetic surfaces that avoid the growth and formation of resistant colonies of bacteria. It’s a tremendous shift from space technology to medical technology that is enabling Genetoo to pioneer a whole new set of applications and develop innovative topographical patterns that will be a welcome solution to the problem of prosthetic infection.
Founded on passion and ingenuity and staffed by an interdisciplinary team from some of the best academic institutions in the world, this license is a perfect fit with Genetoo’s goal of reducing prosthetic infection rates and cutting associated pain and collateral costs. NASA’s proof of concept will soon be forthcoming. Genetoo eagerly anticipates embarking on lab work soon after that will allow them to drive this exciting new biomedical technology.